Colon Adenocarcinoma Clinical Trial
Official title:
VIVA: Volatile or IV Anesthesia for Cancer
This trial evaluates how inhalational anesthesia (drawn in through the lungs) and total intravenous anesthesia (TIVA) (through a needle in a vein in the arm) change the body's ability to recover from surgery or whether they impact the immune system immediately after surgery in patients with colon cancer. It is unknown whether these types of anesthesia change recovery from surgery or change the chances cancer comes back following surgery. This study may help researchers learn how different types of anesthesia affect recovery from colon cancer surgery.
PRIMARY OBJECTIVE: I. To evaluate the differential impact of TIVA versus inhaled anesthesia on neutrophil extracellular traps (NET) inflammation and immunosuppression among patients undergoing cancer surgery. SECONDARY OBJECTIVES: I. To evaluate the differential impact of TIVA versus inhaled total anesthesia choice on patient reported post-operative recovery: Ia. Overall, and domain-specific post-operative recovery (as measured by the Quality of Recovery Score [QoR]-40) on the day of discharge and other post-operative timepoints; Ib. Changes in overall and domain-specific post-operative recovery over time. II. To evaluate the differential impact of TIVA versus inhaled total anesthesia choice on peri-operative clinical and anesthetic outcomes, as recorded in the electronic medical record (EMR), including: IIa. Post-operative nausea and vomiting (from medical record); IIb. Post-operative pain (measured on a 1-10 scale) (from medical record); IIc. Return of gastrointestinal (GI) function (from medical record); IId. Post-operative cognitive impairment (from medical record); IIe. 30 and 90 days post-operative complications; IIf. Disease-free survival (from medical record); IIg. Overall survival (from medical record). III. To evaluate the differential impact of TIVA versus inhaled total anesthesia choice on circulating levels of inflammatory cytokines, immune cell populations, global inflammatory markers. IV. To evaluate the differential impact of TIVA versus inhaled total anesthesia choice on levels of circulating tumor DNA (ctDNA) at multiple post-operative timepoints according to standard of care practices of the University of Kansas Medical Center (KUMC) Division of Medical Oncology GI oncology practice. V. Correlation of peri-operative clinical and anesthetic outcomes to neutrophil extracellular traps (NET) levels, measures of immune suppression, ctDNA. OUTLINE: Patients are randomized to 1 of 2 arms. ARM I: Patients receive standard of care (SOC) sedation with sevoflurane via inhalation and fentanyl intravenously (IV) on study prior to SOC surgery. Some patients may also receive sedation with propofol IV prior to surgery. All patients also undergo blood sample collection throughout the study and collection of tissue sample during surgery. ARM II: Patients receive SOC sedation with fentanyl IV and propofol IV on study prior to SOC surgery. Patients also undergo blood sample collection throughout the study and collection of tissue sample during surgery. After completion of study treatment, patients are followed up at 1 and 3 days, 3 and 6 weeks, 3 and 6 months, and then yearly for 5 years from SOC surgery. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04003181 -
The Pathogenesis of Chronic Diarrhoea After Treatment for Cancer in Cecum and the Ascending Colon
|
N/A | |
Active, not recruiting |
NCT04057274 -
Acute Effect of modeRate-intensity aerOBIc Exercise on Colon Cancer Cell Growth
|
N/A | |
Completed |
NCT02127359 -
Whole-Exome Sequencing (WES) of Cancer Patients
|
||
Completed |
NCT00096278 -
Fluorouracil, Leucovorin, and Oxaliplatin With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II or Stage III Colon Cancer
|
Phase 3 | |
Active, not recruiting |
NCT02912559 -
Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair
|
Phase 3 | |
Completed |
NCT02569723 -
Oxaliplatin Microdosing Assay in Predicting Exposure and Sensitivity to Oxaliplatin-Based Chemotherapy
|
N/A | |
Recruiting |
NCT05746195 -
Optimization of Adaptive Text Messages for Cancer Survivors (OATS II)
|
N/A | |
Active, not recruiting |
NCT03365882 -
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
|
Phase 2 | |
Completed |
NCT02393755 -
Nintedanib and Capecitabine in Treating Patients With Refractory Metastatic Colorectal Cancer
|
Phase 1/Phase 2 | |
Recruiting |
NCT05710406 -
Testing the Use of BRAF-Targeted Therapy After Surgery and Usual Chemotherapy for BRAF-Mutated Colon Cancer
|
Phase 2/Phase 3 | |
Active, not recruiting |
NCT03436563 -
M7824 in Patients With Metastatic Colorectal Cancer or With Advanced Solid Tumors With Microsatellite Instability
|
Phase 1/Phase 2 | |
Recruiting |
NCT05482516 -
Evaluating Novel Therapies in ctDNA Positive GI Cancers
|
Phase 3 | |
Completed |
NCT02368886 -
Lower or Standard Dose Regorafenib in Treating Patients With Refractory Metastatic Colorectal Cancer
|
Phase 2 | |
Active, not recruiting |
NCT02863107 -
Young-Onset Colorectal Cancer
|
||
Active, not recruiting |
NCT04963283 -
Study of Cabozantinib and Nivolumab in Refractory Metastatic Microsatellite Stable (MSS) Colorectal Cancer
|
Phase 2 | |
Recruiting |
NCT06414304 -
Dynamics of MSI and Genomic Profile of Colorectal Cancer In the Course of Immune Checkpoint Inhibitor Therapy
|
||
Completed |
NCT05872334 -
The Safety and Feasibility of MONOFIX on Fascial Closure of Mid-line Wound After Minimally Invasive Colorectal Cancer Surgery
|
N/A | |
Not yet recruiting |
NCT06426927 -
PeLear CCC: Proyecto Latino Contra Cancer Colorectal
|
N/A | |
Completed |
NCT03949777 -
Validation of Aer-O-Scope Colonoscope System Cecal Intubation
|
N/A | |
Completed |
NCT06216405 -
Performance of Artificial Intelligence in Colonoscopy for Right Colon Polyp Detection
|
N/A |